Search

everythinglearnresearchcommunity

for

Search:↓

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Serum triglyceride levels are not linked to prostate cancer risk.

Male pattern baldness may predict prostate cancer risk.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Men with male pattern baldness have a higher risk of certain skin cancers, especially on the scalp.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

ERG increases SOX9, promoting prostate cancer growth and invasion.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Suppressing certain hormones might help prevent prostate cancer.